James Lee, MD

InstitutionUniversity of California San Francisco
Address513 Parnassus Ave
San Francisco CA 94143
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    2006  - 2007American Medical Association Seed Grant
    2006  - 2007American Society of Hematology Trainee Award
    2007  - 2008Farr Scholar Award for Leadership and Excellence in Biomedical Research, Yale University
    2008  - 2009American Cancer Society of Connecticut Research Award
    2016  - 2017NIH Immunology T32
    2017  - 2019A.P. Giannini Fellowship Award

    Collapse Overview 
    Collapse Overview
    I have a research focus in adoptive T cell therapy using chimeric antigen receptors (CARs) and checkpoint inhibitors. My current interest is on the design of next generation of CARs and combination checkpoint immunotherapy in the setting of a tolerant/suppressive tumor microenvironment in solid malignancies.

    Translating recent advancements in cellular cancer immunotherapy to metastatic solid tumors has been especially challenging, and this is highlighted by the lack clinical response outside of the CD19 ideal antigen as target. Current forms of therapy is likely insufficient to overcome the naturally tolerogenic microenvironment evolved to protect against autoimmunity. Using the liver as a model organ of immune tolerance, I intend to study the mechanism of tumor escape in the setting of checkpoint inhibition and adoptive T cell therapy.

    My hope is to see cancer immunotherapeutics become its own mainstream cancer subspecialty.

    Professional Experience:

    Clinical Instructor, Memorial Sloan-Kettering Cancer Center, New York, NY. July 2012-July 2013

    Clinical Instructor, University of California, San Francisco, CA. July 2013-July 2014


    Medical School: Yale School of Medicine, New Haven, CT. September 2003-May 2009

    Research Fellowship: Memorial Sloan-Kettering Cancer Center, New York, NY. 2006-2009.

    Residency: Mount Sinai Medical Center, New York, NY. July 2009-June 2012

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018 Jun 24. PMID: 29937434.
      View in: PubMed
    2. Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi AP, Pampaloni M, Alvarado MD, Rosenblum MD, Daud AI. Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight. 2017 07 20; 2(14). PMID: 28724802.
      View in: PubMed
    3. Holohan DR, Lee JC, Bluestone JA. Shifting the Evolving CAR T Cell Platform into Higher Gear. Cancer Cell. 2015 Oct 12; 28(4):401-402. PMID: 26461084.
      View in: PubMed
    4. Lee JC*, Pegram HJ*, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ .Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012; 18(119):4133-41.
    5. Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 2011 Apr 15; 71(8):2871-81. PMID: 21487038; PMCID: PMC3094720.
    6. Santos EB, Yeh R, Lee J, Nikhamin Y, Punzalan B, Punzalan B, La Perle K, Larson SM, Sadelain M, Brentjens RJ. Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med. 2009 Mar; 15(3):338-44. PMID: 19219023; PMCID: PMC2837150.
    7. Lee J, Sadelain M, Brentjens R. Retroviral transduction of murine primary T lymphocytes. Methods Mol Biol. 2009; 506:83-96. PMID: 19110621; PMCID: PMC5003426.
    8. Inventing New CARs: Analysis of Chimeric Antigen Receptor Gene-Targeted T cells Modified to Overcome Regulatory T cell Suppression in the Tumor Microenvironment. Yale University MD Thesis. 2009.
    James's Networks
    Derived automatically from this person's publications.
    People in Profiles who have published with this person.
    Related Authors
    People who share related concepts with this person.